These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 9651163)

  • 21. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide).
    Rewcastle GW; Palmer BD; Dobrusin EM; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1994 Jun; 37(13):2033-42. PubMed ID: 8027985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase.
    Guan H; Laird AD; Blake RA; Tang C; Liang C
    Bioorg Med Chem Lett; 2004 Jan; 14(1):187-90. PubMed ID: 14684325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
    Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
    J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advances in development of antitumor tyrosine kinase inhibitors].
    Uehara Y
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1536-40. PubMed ID: 9309152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
    Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
    Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
    Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
    Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
    Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C
    J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of some 3-(substituted-benzylidene)-1,3-dihydroindolin derivatives as ligands of tyrosine kinase based on binding mode studies and biological assay.
    Olgen S
    Arch Pharm Res; 2006 Nov; 29(11):1006-17. PubMed ID: 17146970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.
    Palmer BD; Rewcastle GW; Thompson AM; Boyd M; Showalter HD; Sercel AD; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1995 Jan; 38(1):58-67. PubMed ID: 7837241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones.
    Ngai MH; So CL; Sullivan MB; Ho HK; Chai CL
    ChemMedChem; 2016 Jan; 11(1):72-80. PubMed ID: 26593399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors.
    Brunton VG; Kelland LR; Lear MJ; Montgomery GJ; Robertson JH; Robins DJ; Queen J; Workman P
    Anticancer Drug Des; 1996 Jun; 11(4):265-95. PubMed ID: 8679052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.